University of Pennsylvania researchers have identified what may be a more effective way to help people quit smoking. About 70 percent of smokers give up the daunting effort during the first week of trying.
The researchers, led by Caryn Lerman, a professort of psychiatry, divided 1,246 subjects into slow metabolizers of nicotine and normal metabolizers of the addictive chemical, based on the length of time it took for them to rid their bodies of the drug. The ratio of two metabolites, or byproducts, of the body’s processing of nicotine allows easy identification of the two groups. The metabolite is found in blood and saliva.
The results of the comparison showed that slow metabolizers did just as well on a nicotine patch or the drug varenicline (marketed as Chantix), a drug that works on the nicotine receptors in the brain. But the patch costs less and has fewer side-effects than varenicline (including nausea, difficulty sleeping and abnormal dreams), so the researchers concluded that slow metabolizers should be put on the patch.
Normal metabolizers of nicotine, meanwhile, had more success with varenicline because they tend to rid their systems of nicotine faster, limiting the effectiveness of the patch. Varenicline contains no nicotine.